Xtalks Webinar: December 2, 2022

Post-Diagnosis Cancer Management Requires More Than Recurrence Detection

Webinar

Dan Norton

Dan Norton
Associate Director, Product Management
Personalis, Inc.

Friday, December 2  | 1:00 PM ET

Post-Diagnosis Cancer Management Requires More Than Recurrence Detection

MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.

In this webinar you’ll learn about the role of next generation liquid biopsy assays in enabling:

  • Earlier detection of disease recurrence
  • Utility in more disease indications, and at earlier stages of disease
  • Patient enrichment, screening/enrollment, and surrogate endpoint analysis for clinical trials
  • Higher resolution variant tracking
  • Combining plasma and tissue analyses